64263-81-6

Basic information

• Product Name: Boc-N-alpha-methyl-O-benzyl-L-tyrosine
• Synonyms: BOC-N-ME-TYROSINE(BZL)-OH;BOC-N-METHYL-O-BENZYL-L-TYROSINE;BOC-L-METYR(BZL)-OH;BOC-N-ALPHA-METHYL-O-BENZYL-L-TYROSINE;BOC-METYR(BZL)-OH;N-ALPHA-1-BUTOXYCARBONYL-N-ALPHA-METHYL-O-BENZYL-L-TYROSINE;N-ALPHA-BOC-O-BENZYL-N-ALPHA-METHYL-L-TYROSINE;N-ALPHA-T-BOC-N-ALPHA-METHYL-O-BENZYL-L-TYROSINE
• CAS NO: 64263-81-6
• Molecular Formula: C₂₂H₂₇NO₅
• Molecular Weight: 385.45
• Product Categories: Tyrosine [Tyr, Y];N-Methyl Amino Acids;Boc-Amino acid series;amino acids
• Mol File: 64263-81-6.mol

Chemical Properties

• Melting Point: 130-134 °C
• Boiling Point: 533 °C at 760 mmHg
• Flash Point: 276.2 °C
• Appearance: /
• Density: 1.174 g/cm³
• Vapor Pressure: 3.42E-12mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: Store at 0-5°C
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: Boc-N-alpha-methyl-O-benzyl-L-tyrosine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-N-alpha-methyl-O-benzyl-L-tyrosine(64263-81-6)
• EPA Substance Registry System: Boc-N-alpha-methyl-O-benzyl-L-tyrosine(64263-81-6)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 64263-81-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Boc-N-alpha-methyl-O-benzyl-L-tyrosine is used as a reactant/reagent for the total synthesis of marine-derived elastase inhibitor lyngbyastatin 7. Boc-N-alpha-methyl-O-benzyl-L-tyrosine exhibits in vitro antiproteolytic activity against porcine pancreatic elastase, making it a valuable component in the development of potential therapeutic agents for various diseases associated with elastase overactivity.

InChI:InChI=1/C22H27NO5/c1-22(2,3)28-21(26)23(4)19(20(24)25)14-16-10-12-18(13-11-16)27-15-17-8-6-5-7-9-17/h5-13,19H,14-15H2,1-4H3,(H,24,25)/t19-/m1/s1

Upstream product

• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 74-88-4 methyl iodide 
• 63769-58-4 (R)-3-(4-benzyloxy-phenyl)-2-tert-butoxycarbonylamino-propionic acid 
• 27513-44-6 N-tert-butoxycarbonyl-O-benzyl-(S)-tyrosine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-39-0 benzyl bromide 
• 60-18-4 L-tyrosine 
• 3978-80-1 Boc-Tyr-OH 
• 251555-87-0 C₂₃H₂₉NO₅ 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 

Downstream Products

• 130816-72-7 Boc-MeTyr(Bzl)-Gly-Gly-OH 
• 82154-41-4 BOC-MeTyr(Bzl)-OTCP 
• 161284-67-9 Boc-(S)-MeTyr(Bzl)-(S)-Tyr(Bzl)-OMe 
• 185448-81-1 (S)-2-[(S)-3-(4-Benzyloxy-phenyl)-2-(tert-butoxycarbonyl-methyl-amino)-propionyloxy]-3-methyl-butyric acid 2-trimethylsilanyl-ethyl ester 
• 178208-43-0 (S)-2-(tert-Butoxycarbonyl-methyl-amino)-3-(4-hydroxy-phenyl)-propionic acid pentafluorophenyl ester 
• 178208-47-4 3-fluoro-4-nitro-N-[N-(tert-butyloxycarbonyl)-N-methyl-L-tyrosyl]-D-phenylalanine methyl ester 
• 178208-45-2 3-fluoro-4-nitro-N-[N-(tert-butyloxycarbonyl)-N-methyl-L-tyrosyl]-L-phenylalanine methyl ester 
• 161284-68-0 Boc-(S)-Val-(S)-MeTyr(Bzl)-(S)-Tyr(Bzl)-OMe 
• 161284-69-1 Boc-(S)-Ala-(S)-Val-(S)-MeTyr(Bzl)-(S)-Tyr(Bzl)-OMe 
• 161346-20-9 (2R,3S)-microginin 
• 170353-61-4 (S)-2-[(S)-2-({(S)-2-[(S)-2-((2R,3R)-3-Azido-2-hydroxy-decanoylamino)-propionylamino]-3-methyl-butyryl}-methyl-amino)-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-benzyloxy-phenyl)-propionic acid methyl ester 
• 170553-77-2 (S)-2-[(S)-2-({(S)-2-[(S)-2-((2R,3S)-3-Azido-2-hydroxy-decanoylamino)-propionylamino]-3-methyl-butyryl}-methyl-amino)-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-benzyloxy-phenyl)-propionic acid methyl ester 
• 170553-79-4 (S)-2-[(S)-2-({(S)-2-[(S)-2-((2S,3R)-3-Azido-2-hydroxy-decanoylamino)-propionylamino]-3-methyl-butyryl}-methyl-amino)-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-benzyloxy-phenyl)-propionic acid methyl ester 
• 170553-78-3 (S)-2-[(S)-2-({(S)-2-[(S)-2-((2S,3S)-3-Azido-2-hydroxy-decanoylamino)-propionylamino]-3-methyl-butyryl}-methyl-amino)-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-benzyloxy-phenyl)-propionic acid methyl ester 

Relevant articles and documents

O-benzyl-N-tert-butoxycarbonyl-N-methyl-L-tyrosine

The crystal structure of the title compound, alternatively called 3-[4-(benzyloxy)phenyl]-2-(N-tert-butoxycarbonyl-N-methylamino)propionic acid, C22H27NO5, has been studied in order to examine the role of N-methylation as

NOVEL SPIROCYCLIC COMPOUNDS

The present invention relates to new spirocyclic compounds that may be useful in as anti- cancer and anti-microbial agents, to the preparation of the compounds, and to compositions including the compounds. The present invention also relates to the use of the compounds, as well as compositions including the compounds, in treating or preventing cancer, and treating or preventing microbial infections.

Naamine derivatives, preparation method of Nammine derivatives, and application of Nammine derivatives in treatment of plant viruses and bacterial diseases

The invention discloses Naamine derivatives, a preparation method of the Nammine derivatives, and an application of the Nammine derivatives in treatment of plant viruses and bacterial diseases. The Nammine derivatives specifically are compounds represented as formulae from I-1 to I-16. During each reaction, materials participating in the reaction are taken according to the molar ratio required bythe reaction; excess substances are selected to participate in the reaction so as to ensure the reaction process of a target product; the pH value and reacting temperature and time of a system are determined according to the reaction type; and purifying separation or drying is carried out after the preparation. The Naamine derivatives provided by the invention exhibit good activity for treating plant viruses and bacterial diseases, and can well inhibit the following 14 species of plant pathogenic bacteria: tobacco mosaic virus (TMV), Fusarium oxysporum (Schl.)F.sp cucumerinum Owen, cercosporaarachidicola, Botryospuaeria berengeriana, Rhizotonia cerealis van der Hoeven apud.Boerema & Verhoeven, Helminthosporium maydis Nisik & Miy, Colleetotrichum lagenarium (Pass.) Ell. et Halst, fusariummoniliforme, Alternaria solani, FusaHum graminearum, Phytophthora infestans, phytophthora capsici, sclerotinia sclerotiorum, Botrytis cinerea and Thanatephorus cucumeris.

Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases

Studies indicate that MAO-B is induced in peripheral inflammatory diseases. To target peripheral tissues using MAO-B inhibitors that do not permeate the blood-brain barrier (BBB) the MAO-B-selective inhibitor deprenyl was remodeled by replacing the terminal acetylene with a CO2H function, and incorporating a para-OCH2Ar motif (compounds 10a-s). Further, in compound 32 the C-2 side chain corresponded to CH2CN. In vitro, 10c, 10j, 10k, and 32 were identified as potent reversible MAO-B inhibitors, and all four compounds were more stable than deprenyl in plasma, liver microsomal, and hepatocyte stability assays. In vivo, they demonstrated greater plasma bioavailability. Assessment of in vitro BBB permeability showed that compound 10k is a P-glycoprotein (P-gp) substrate and 10j displayed mild interaction. Importantly, compounds 10c, 10j, 10k, and 32 displayed significantly reduced BBB permeability after intravenous, subcutaneous, and oral administration. These polar MAO-B inhibitors are pertinent leads for evaluation of efficacy in noncentral nervous system (CNS) inflammatory disease models.

An expeditious synthesis of the ascomycete metabolite rigidiusculamide B

The ascomycete metabolite rigidiusculamide B was synthesised in six steps and 22% overall yield. The key steps were a Li2Te-triggered Dittmer-type Dieckmann cyclisation of an N-(α-haloacyl)tyrosine ester to give a 4-O-silyl tetramate, followed

MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF

Described herein are a series of compounds having the structure of Formula I for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

A simple and rapid protocol for N-methyl-α-amino acids

A two step strategy for optically pure N-Protected-N-methyl-α-amino acids starting from N-protected-α-amino acids via reductive cleavage of oxazolidinones using NaCNBH3/TMSCl is described.

Synthesis of (9R,12S)- and (9S,12S)-cycloisodityrosine and their N-methyl derivatives

Full details of the synthesis of (9R,12S)- and (9S,12S)-cycloisodityrosine and their N-methyl derivatives are detailed based on an intramolecular nucleophilic aromatic substitution reaction for formation of the key biaryl ether with 14-membered ring macrocyclization. Their comparison with prior samples and the documentation of a facile C9 epimerization within the natural 9S series are described.

SYNTHESIS OF CYCLO-N-METHYL-L-TYR-N-METHYL-L-TYR-D-ALA-L-ALA-O,N-DIMETHYL-L-TYR-L-ALA, A CYCLIC HEXAPEPTIDE RELATED TO THE ANTITUMOR AGENT DEOXYBOUVARDIN

A synthesis of the title cyclic hexapeptide is described.Its lack of antitumor activity shows that the 14-membered ring of deoxybouvardin is needed for activity.Efforts to oxidatively its phenolic groups failed to give deoxybouvardin.